Long-term safety of approved biologics for ulcerative colitis.
Ferdinando D'AmicoTommaso Lorenzo ParigiStefanos BonovasLaurent Peyrin-BirouletSilvio DanesePublished in: Expert opinion on drug safety (2020)
Biologics long-term safety is consistent with what expected from shorter term studies and no main new concerns emerged from longer follow-up. Real world experience is consistent with clinical trials data. Although comparisons are difficult, safety profiles are not equal among different biologics.